Background. The target enzyme of pyrimethamine is dihydrofolate reductase (DHFR), but little is known about allelic variants of dhfr in Plasmodium vivax populations. Still less is known about associations between specific alleles and the failure of sulfadoxine/pyrimethamine (S/P) to clear the erythrocytic stages of P. vivax in vivo.
fadoxine and pyrimethamine (S/P), is not recommended for therapy of P. vivax malaria (vivax malaria) [4] , on the basis of its historically poor demonstrated efficacy [5] [6] [7] [8] [9] . However, in areas of endemicity, S/P is widely used to treat chloroquine-resistant malaria caused by Plasmodium falciparum. Where these species occur together, P. vivax may often be treated with S/P, either because of mixed infection, inaccurate diagnosis, or economic issues. The risk of therapeutic failure associated with the use of S/P for P. vivax affects strategies for malaria-treatment policies. Molecular probes that reliably predict susceptibility of P. vivax to S/P would provide information supporting rational policy decisions and practice with regard to malaria treatment.
S/P resistance in P. vivax also poses important questions with regard to the development of new antimalarial drugs. Drugs that are effective against both P. falciparum and P. vivax offer obvious advantages in areas where these infections occur together-notably, in southern Asia and South America. The most conspicuous advantage is that appropriate therapy would not hinge on an accurate diagnosis of the parasite species. The dihydrofolate reductase (DHFR; E.C. 1.5.1.3) enzyme of plasmodia is the therapeutic target of the pyrimethamine component of S/P [10] . Extensive laboratory and field studies of P. falciparum have demonstrated that resistance to pyrimethamine is caused by dhfr alleles that carry specific point mutations [11] [12] [13] [14] [15] [16] [17] . In P. falciparum, clinical resistance to S/P apparently requires an accumulation of у3 mutations in dhfr [18] , and the resistance is augmented by additional mutations in dihydropteroate synthase, the target of sulfadoxine [19] [20] [21] . DHFR in P. vivax has not been evaluated as thoroughly as that in P. falciparum, but mutant alleles are prevalent in Southeast Asia [7, [22] [23] [24] [25] [26] [27] , and mutations at positions 57, 58, and 117 have been associated with antifolate resistance [7, 26] . One study suggested that parasites that carry the wild-type dhfr allele are susceptible to S/P, as are parasites with alleles that contain 1 or 2 mutations [7] . WR99210 is a novel antifolate drug with potent activity against S/P-resistant P. falciparum [28] , and analogues of WR99210 currently are in the preclinical phase of development. If drugs of this class exert similar activity against S/P-resistant P. vivax, this finding would greatly increase their potential clinical usefulness [29, 30] The dhfr gene from P. falciparum can be expressed in yeast that lack endogenous DHFR activity. These engineered yeast lines exhibit in vitro susceptibility to antifolate drugs that reflects the susceptibility of the parasite from which the dhfr allele was isolated [31, 32] . We have previously used this assay system to evaluate several alleles of P. vivax dhfr for susceptibility to pyrimethamine, chlorcycloguanil, and WR99210 [30] . The P. vivax dhfr alleles evaluated in the present study were cloned and sequenced from the blood of patients in Indonesia who were treated with S/P and observed for 28 days. Some alleles were also generated by site-directed mutagenesis, to assess the relative impact of individual mutations in alleles with multiple mutations. This approach permitted both assessment of the efficacy of S/P treatment for P. vivax infections and linkage of in vitro findings with therapeutic outcomes, thus allowing for a rational assessment of the potential therapeutic efficacy of WR99210 in the treatment of infection due to S/P-resistant P. vivax.
SUBJECTS, MATERIALS, AND METHODS
Subjects and therapeutic classification. The parasites evaluated in the present study were obtained from a subset of samples from clinical studies conducted in the Armopa region of northeastern Papua, Indonesia (from 1996 through 1999), and in Purworejo in southern Central Java, Indonesia (in 2000). These studies have been described elsewhere [33, 34] . The parasites evaluated in the present study were obtained from available samples from all subjects who received standard S/P therapy for slide-and polymerase chain reaction (PCR)-proven P. vivax infection. S/P therapy was not indicated for vivax malaria in these studies, but the subjects received it as a result of either an error in initial diagnosis by microscopic examination or the therapeutic precedence of mixed infection with P. falciparum, according to study protocol.
Subjects in the clinical studies were followed, by microscopic examination, for 28 days (with such examinations performed on days 0-4, 7, 11, 14, 18, 21, and 28, or on any day when subjects were ill), after they received directly observed S/P therapy (single dose: [25 mg sulfadoxine + 1.25 mg pyrimethamine]/kg body weight). We classified therapeutic outcomes as (1) "susceptible," if parasitemia cleared by day 4 and did not reappear by day 28; (2) "responsive," if parasitemia cleared by day 4 but reappeared between days 8 and 28; and (3) "resistant," if parasitemia either failed to clear by day 4 or cleared but then reappeared by day 7. Susceptible and resistant classifications represented firm, but not entirely unambiguous, characterizations of the therapeutic response to S/P. Rapid clearance of parasitemia and failure of parasitemia to reappear by day 28 were consistent with a susceptible response, but they did not preclude the possibility of recrudescence (as subpatent parasitemia) beyond day 28. Failure of parasitemia to clear by day 4 or reappearance of parasitemia by day 7 was consistent with therapeutic failure but did not preclude emergence of parasitemia caused by reinfection or relapse in subjects exposed to continuous risk of infection. Infections classified as responsive were considered to be either moderately, but not completely, susceptible to S/P or confounded by reinfection and relapse.
Cloning and sequencing of DHFR. Genomic P. vivax DNA was extracted from dried blood blots on filter paper, by use of the blood blot DNA extraction protocol from a commercial kit (QIAamp DNA Mini Kit; Qiagen). The dhfr gene was then amplified by PCR in a 100-mL reaction, with 2 mL of Taq polymerase (Promega), 10 mL of 10ϫ PCR buffer, 8 mL of 25 mmol/ L MgCl 2 , 1 mL of 10 mmol/L each primer, 1 mL of 10 mmol/L each dNTP, 10 mL of template DNA, and 67 mL of PCR H 2 0. The primers used were as described elsewhere [30] . The 5 end of each primer is complementary to the sequence of the shuttle plasmid at the desired insertion position, to facilitate homologous recombination in yeast [35, 36] . The cycling parameters were as follows: (1) initial denaturation at 94ЊC for 3 min, followed by 5 cycles of denaturation at 94ЊC for 1 min, elongation at 60ЊC for 1 min, and extension at 72ЊC for 1 min; (2) 5 cycles of denaturation at 94ЊC for 1 min, elongation at 55ЊC for 1 min, and extension at 72ЊC for 1 min; and (3) 20 cycles of denaturation at 94ЊC for 1 min, elongation at 55ЊC for 1 min, and extension at 72ЊC for 1 min.
The Saccharomyces cerevisiae yeast strain that was used lacks endogenous DHFR activity and has been described elsewhere [30, 32] . Yeast were transformed using a high-efficiency lithium acetate protocol [37] ; they then were plated onto medium that lacked tryptophan, to select for the plasmid, and that also lacked deoxythymidine monophosphate, to select for functional DHFR activity. Escherichia coli strain DH5a was used for propagation and preparation of the shuttle plasmid from the transformed yeast. The plasmid was isolated and purified from the bacteria by use of a commercial kit (QIAprep Spin Miniprep Kit; Qiagen). Sequencing was conducted by fluorescent dye chemical analysis (MegaBACE; Amersham Pharmacia Biotech), and sequences were analyzed using Sequencher software (Gene Codes). At least 4 isolates from each patient sample were sequenced to check for mixed genotypes; if the 4 isolates were not all in agreement, then an additional 4-7 isolates were sequenced to verify the mixed genotype. Site-directed mutagenesis (QuikChange; Stratagene) was used to engineer mutations into the wild-type dhfr sequence, for generating alleles not found in the patient samples.
The work with human subjects in this study was reviewed (protocols DoD #30820 and DoD #30839) and approved by US Navy and Indonesian institutional review boards. All subjects provided written informed consent to participate in the study, in accordance with US Navy regulations governing the use of human subjects for medical research (SECNAVINST 3900.39C).
In vitro susceptibility classification. The IC 50 assays were performed as described elsewhere [38] , to obtain quantitative measures of drug susceptibility. The growth of the yeast in this assay depends on the antifolate resistance of the dhfr allele expressed. In the present study, an "IC 50 " is defined as the concentration of drug at which the growth of the yeast culture is inhibited by 50% relative to that of the untreated control. Yeast transformed with dhfr from P. vivax were grown overnight in a 96-well culture dish in complete medium (yeast extract, peptone, and dextrose [YEPD] broth) lacking dTMP. The growth of the yeast in each well was assessed by spectrophotometry after incubation at 30ЊC for ∼24 h, which is the amount of time required for the untreated control yeast to reach midlog phase. The average reading for each allele at each drug concentration was then used to plot the percent growth relative to that of the control. The numerical IC 50 value was calculated from the slope and the intercept of the line defined by the 2 data points that bracket 50% relative growth. Comparisons of the IC 50 values of the mutant alleles with those of the wildtype allele were used to assess the relative drug-resistance level of each allele. IC 50 assays were performed at least twice for each allele, to determine the SD and to ensure reproducibility.
Assessment of the therapeutic risk of DHFR mutations. The odds ratio (OR) for therapeutic failure, relative to the dhfr allele, was calculated by standard analyses. We report 95% 2 x confidence intervals (CIs) for the OR and a P value calculated by 2-tailed Fisher's exact test, by use of EpiInfo software, version 7.0. (public domain software; US Centers for Disease Control and Prevention).
, along with a 95% CI that excludes P ! .05 1.0, was considered to be consistent with an association between an allele and therapeutic outcome.
RESULTS
Parasitologic response to S/P. The primary goal was to classify the therapeutic response to S/P treatment for infections with P. vivax. Table 1 classifies the responses of the 24 subjects evaluated. Ten subjects exhibited responses that were consistent with S/P susceptibility, 5 subjects had recurrent parasitemia that was classified as responsive, and 9 subjects had S/P-resistant infections.
dhfr Alleles. Six alleles, including wild-type alleles, were isolated from the samples collected immediately before S/P therapy was administered (table 1) . Five (21%) of the 24 patient samples contained P. vivax with mixed dhfr genotypes, indicating a polyclonal infection. Three of the alleles (58R+ 117N+99S, 58R+117N+199V, and 57L+58R+61M+117T) are novel for this species or have only very recently been described. The presence of 99S and 199V mutations has not been previously reported. The 2 most prevalent alleles in this sample were 58R+117N and 57L+58R+61M+117T; these alleles account for 22 of the 29 alleles (13 of the alleles were 58R+117N, and 9 were 57L+58R+61M+117T). The wild-type allele was found only once, whereas the 58R, 58R+117N+199V, and 58R+117N+99S alleles were each observed twice. The doublemutant allele isolated from sample UW16 had an additional silent mutation (GGTrGGC) at codon 101; this was the only silent change that was observed. We observed 3 different codons that all encoded the arginine amino-acid change at position 58. The AGCrAGA mutation was present in all 58R single-mutant alleles and 58R+117N+199V triple-mutant alleles, as well as in 1 double-mutant allele found in a mixed sample with a 58R+117N+199V allele (UW19). The double-mutant allele isolated from sample UW14 carried an AGCrCGC mutation at codon 58. All 58R+117N+99S and 57L+58R+61M+117T alleles shared the AGCrAGG mutation at position 58.
dhfr Alleles and clinical response to S/P. Table 1 lists the dhfr genotype(s) and therapeutic response of each isolate evaluated. Of the 9 patients with parasites that contained quadruplemutant dhfr alleles, 7 showed responses consistent with S/P resistance, whereas the remaining 2 showed responses that were fully susceptible. Of the infections associated with the 15 isolates with only wild-type, single, double, or triple mutations in dhfr, only 2 infections showed therapeutic responses that were consistent with resistance to S/P. Of parasites from 9 infections that were classified as resistant, 7 carried the quadruple mutation. Three of 5 parasites classified as being responsive to treatment carried either a triple-or quadruple-mutant allele, and only 3 of 10 classified as susceptible carried either a tripleor quadruple-mutant allele. Parasites that carried highly mutant alleles of dhfr appeared to be more resistant to S/P treatment. Table 2 compares the risk of therapeutic failure when parasites carry the quadruple-mutant allele relative to the risk of therapeutic failure when parasites carry any other allele. Polyclonal clearance of parasitemia by day 4, followed by reappearance by day 7; "responsive" denotes clearance of parasitemia by day 4, followed by reappearance between days 8 and 28; and "susceptible" denotes clearance of parasitemia by day 4 and no reappearance of parasitemia by day 28.
infections were classified according to the most highly mutated dhfr allele present. Patients with the quadruple-mutant allele were 23 times more likely to show a poor therapeutic response, compared with patients with other dhfr alleles (table 2; P p ; 95% CI, 2-450). Similarly, when polyclonal infections .003 were excluded from analysis, patients with the quadruplemutant allele were 25 times more likely to show a poor therapeutic response ( ; 95% CI, 2-347). P ! .01 Yeast expression system susceptibility. Susceptibility of P. vivax to antifolates cannot be easily assayed in vitro. We created, as a surrogate, a series of yeast lines that each depend on a different vivax dhfr allele to assess relative in vitro levels of sensitivity to pyrimethamine and the experimental DHFR inhibitor WR99210. Table 3 presents the mean IC 50 values ‫ע(‬ SD) for pyrimethamine and WR99210, in addition to the ratio of resistance, compared with that of the wild type, for each mutant allele.
The yeast line expressing the quadruple-mutant allele 57L+ 58R+61M+117T did not demonstrate any significant inhibition of growth at drug concentrations of up to 500 mmol/L pyrimethamine. Therefore, the enzyme encoded by this quadruplemutant allele is 1500 times more resistant to pyrimethamine than is the wild type. To investigate whether the novel 61M mutation contributes to this high level of resistance, we constructed the triple-mutant allele 57L+58R+117T (which lacks the 61M mutation) by use of site-directed mutagenesis. This allele was significantly less resistant than the quadruple-mutant allele (270-fold vs. 1500-fold). We also constructed alleles with the 58R+117T mutations and the 117T mutation alone. Both showed relatively modest resistance to pyrimethamine (40-43-fold greater than resistance of the wild type).
The 117T allele conferred slight (1.6-fold) resistance to WR99210, whereas the 58R+117T double-mutant allele conferred a 10-fold increase in resistance to WR99210. The addition of the 57L mutation to create the 57L+58R+117T allele decreased resistance to WR99210 (5-fold more than the wild type). Finally, the quadruple-mutant allele 57L+58R+61M+ 117T, which is essentially insensitive to pyrimethamine in this system, showed an ∼90-fold increased level of resistance to WR99210, compared with the wild type.
We determined the in vitro sensitivities to pyrimethamine and WR99210 of the novel triple-mutant alleles (58R+117N+ 99S and 58R+117N+199V), relative to those of the doublemutant allele (58R+117N). All 3 alleles show high levels of resistance to pyrimethamine, ranging from 80-fold to 240-fold resistance, compared with the wild type. The addition of the 99S mutation to the 58R+117N allele did not increase resistance to pyrimethamine, but the addition of the 199V mutation produced an allele with an IC 50 value that was more than twice that of the double mutant. All 3 alleles were more sensitive to WR99210 than was the wild-type allele (table 3) . The 58R single-mutant allele was slightly more resistant to pyrimethamine (1.3-fold more resistant) than was the wild-type allele in the yeast system, whereas it was 8.5-fold more resistant to WR99210 than was the wild type.
DISCUSSION
Six different alleles of dhfr were found in this sample of 24 isolates of P. vivax from Indonesia. Subjects infected by parasites clearance of parasitemia by day 4, followed by reappearance by day 7; "responsive" denotes clearance of parasitemia by day 4, followed by reappearance between days 8 and 28; and "susceptible" denotes clearance of parasitemia by day 4 and no reappearance of parasitemia by day 28. c Calculated by standard analysis. that carried the quadruple-mutant allele 57R+58L+61M+117T were 23 times more likely to experience therapeutic failure, compared with subjects infected by parasites that carried only wild-type, single-, double-, or triple-mutant alleles of dhfr. Two subjects infected by parasites that carried the quadruple-mutant allele had a good therapeutic response, and this may reflect the operation of host factors (e.g., immunity) as contributing determinants of therapeutic outcomes. Of the 15 subjects who carried only parasites with wild-type, single, double, or triple mutations in dhfr, only 2 showed therapeutic responses that were consistent with resistance. Those exceptional outcomes could be the result of one of any number of explanations, such as poor absorption of drug or efficient use of exogenous folate by the parasites. In addition, like most studies evaluating the efficacy of drugs against P. vivax, accurate designation of clinical outcomes as treatment failures was limited by the possibility of early relapse and reinfection in evaluated cases. The trends detected in our sample nonetheless point to dhfr genotype in P. vivax as a probable determinant of therapeutic outcome with S/P.
The poor therapeutic response to S/P by P. vivax was documented in early studies [5, 9] . S/P is not recommended for treatment of vivax malaria [4] . Recent studies in Thailand, which demonstrated clinical efficacy of just 40% and 31%, corroborate that view [6, 7] . An intervention employing mass administration of S/P and primaquine in northern Sumatra, Indonesia, sharply reduced falciparum malaria but not vivax malaria [8] . Although such findings are often attributed to an inherent tolerance of pyrimethamine by P. vivax [5, 9] , recent studies point to dhfr mutations as the more likely explanation [7, 26] . This is an important point that bears directly on approaches to discovery of drugs for the treatment of vivax malaria. If the molecular basis of poor therapeutic response is understood, it may be addressed in drug design and in vitro assessment. This was the rationale behind our assessment of dhfr alleles in a yeast expression system allowing relative measures of DHFR inhibition by antifolates.
The in vitro yeast expression assay system made it possible to dissect the contributions of specific mutations to DHFR inhibition and, presumably, therapeutic outcome. We detected 58R alleles in parasites from 2 clinically resistant infections mixed with triple-or quadruple-mutant alleles and, thus, could not assess the role of the 58R mutation in that therapeutic outcome. However, the 58R mutation had a negligible effect on pyrimethamine sensitivity in the yeast system. The 99S mutation did not confer additional resistance to pyrimethamine, compared with that conferred by the double-mutant allele 58R+117N. This finding is consistent with the fact that the mutation occurred in a region that is prone to insertion and deletion events [22, 27] (M.D.H., unpublished data) and, apparently, is located peripheral to the folate-binding pocket of the enzyme (C.H.S., unpublished data). In contrast, the in vitro analyses revealed that the 61M mutation is an important contributing factor to DHFR inhibition by pyrimethamine: 57L+58R+117T showed 270-fold resistance, whereas 57L+58R+ 61M+117T showed 1500-fold resistance.
The in vitro analyses of the inhibition of dhfr mutants by WR99210 point to a high probability of therapeutic efficacy against S/P-susceptible and -resistant P. vivax. The poor therapeutic response of P. vivax to S/P is evidently linked to the quadruple-mutant allele of the dhfr gene, and these data, along with the data from several recent studies, suggest that this quadruple-mutant allele may be widespread in Southeast Asia [26, 27] . The quadruple-mutant allele also showed the highest level of in vitro resistance to WR99210, relative to the other 5 alleles. However, the IC 50 value for this allele was only 92 times greater than the IC 50 value measured for the wild type, whereas no other allele was 110-fold more resistant than the wild type. S/P was still clinically effective against parasites carrying alleles that were 80-240-fold more resistant to pyrimethamine than was the wild type. If this ratio of effectiveness is also observed for drugs of the WR99210 class, even parasites that carry the quadruple-mutant allele might be successfully treated with a drug of this kind. As development of these drugs proceeds, testing their effectiveness against strains of P. vivax that are highly resistant to pyrimethamine should be a high priority.
The clinical findings reported in the present study provide a benchmark for correlation with findings of the in vitro yeast expression assay [30] . The in vitro inhibition of expressed DHFR mutants correlated well with the clinical outcomes of parasite populations carrying the corresponding alleles. For example, the dhfr double-mutant allele 58R+117N was 100-fold more resistant to pyrimethamine than the was wild-type allele in the in vitro assay, and the triple-mutant allele 58R+ 117N+99S had a similar resistance level; clinical isolates that carried these alleles were generally susceptible or responsive to S/P treatment. In contrast, the quadruple mutant was 1500 times more resistant to pyrimethamine in yeast and exhibited very poor clinical response to S/P treatment. These data will allow an estimation of the in vivo S/P susceptibility of P. vivax parasites that carry a novel allele of dhfr, by determining the relative level of pyrimethamine resistance in the yeast expression system. As in other studies using sequence analysis of dhfr, in the present study, we detected novel alleles [26, 27] . The diversity of mutations in dhfr is apparently rich in natural parasite populations, and allele-specific methods do not reveal this diversity. For example, position 117 of P. vivax dhfr corresponds to position 108 in the P. falciparum enzyme. In P. falciparum, highly pyrimethamine-resistant alleles carry an asparagine at this position. Therefore, the frequent finding of the threonine mutation in the P. vivax isolates evaluated in the present study was quite unexpected. An allele-specific PCR protocol was initially used to characterize P. vivax dhfr alleles in Thailand, on the basis of a P. falciparum model, under the assumption that triple mutants that did not carry the wild-type serine at position 117 had a mutation to asparagine [7] . When the entire coding sequence was determined, it was found that these alleles, in fact, carried a threonine at position 117 [27] . This difference emphasizes the importance of direct sequence analysis of P. vivax dhfr, because P. vivax has greater allelic diversity than is found in P. falciparum.
In summary, of the 6 different alleles that were detected in 24 patient samples from Papua and Central Java, Indonesia, only the quadruple-mutant allele was linked to a high risk of therapeutic failure of S/P. The yeast in vitro expression system allowed us to examine, in detail, the response of the various alleles to both S/P and WR99210, and there was a strong correlation between the therapeutic response to S/P and the susceptibility of yeast lines carrying the various alleles. The in vitro system also allowed us to predict that the experimental DHFR inhibitor, WR99210, is likely to demonstrate good clinical efficacy against P. vivax parasites carrying the S/P-resistant quadruple mutant reported in the present study. Furthermore, WR99210 may be particularly effective against parasites carrying the double-and triple-mutant alleles. The effectiveness of WR99210 against the alleles of P. falciparum dhfr that are most resistant to pyrimethamine is well established [31, 39] , and extending that effectiveness to treatment of P. vivax infections is an exciting possibility [29] .
